GS Choi, et al

	Dutasteride	Finasteride	Unadjusted incidence rate ratio* (95% CI) <i>p</i> -value	Adjusted incidence rate ratio* (95% CI) <i>p</i> -value
			Dutasteride is more effective than finasteride	Dutasteride is more effective than finasteride
BASP basic type	78	67		
Patients with improvement in BASP basic type, n (%)	63 (80.8)	32 (47.8)	⊢ <b>−</b> −−−− 2.88 (1.88, 4.41) <0.001 <sup>‡</sup>	1.84 (1.07, 3.17) 0.028 <sup>↑</sup>
IR of improvement in BASP basic type, 100 PPPY	70.55	24.49		
Basic M type	76	65		
Patients with improvement in basic M type, n (%)	61 (80.3)	31 (47.7)	► ► 2.89 (1.88, 4.46) <0.001 <sup>‡</sup>	<b>1.84 (1.06, 3.21) 0.031</b> <sup>+</sup>
IR of improvement in basic M type, 100 PPPY	70.76	24.47		
BASP specific V type	79	37		
Patients with improvement in V type, n (%)	73 (92.4)	23 (62.2)	↓ 2.79 (1.75, 4.46) <0.001 <sup>‡</sup>	⊢ <b>−−−−−</b> −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
IR of improvement in V type, 100 PPPY	99.67	35.72		
BASP specific F type	81	39		
Patients with improvement in F type, n (%)	69 (85.2)	22 (56.4)	<b>1</b> 2.36 (1.46, 3.82) <0.001 <sup>‡</sup>	1.41 (0.76, 2.60) 0.271
IR of improvement in F type, 100 PPPY	79.62	33.69	0 1 2 3 4 5	
			Incidence rate ratio	Incidence rate ratio

Supplementary Fig. 2. Effectiveness of dutasteride and finasteride among all patients. CI: confidence interval, BASP: basic and specific classification, IR: incidence rate, PPPY: per-person per-year. \*Multivariate models were adjusted for age at index date, study site, index year, any recent hair loss at baseline, any comorbidities at baseline, use of any treatment during baseline, and baseline severity of androgenic alopecia. Missing and 'no' values were combined into a single category for each variable. <sup>+</sup>Significant at the 0.05 level. <sup>+</sup>Significant at the 0.001 level.